NO314783B1 - Farmasoytiske formuleringer inneholdende darifenacin - Google Patents
Farmasoytiske formuleringer inneholdende darifenacin Download PDFInfo
- Publication number
- NO314783B1 NO314783B1 NO19981073A NO981073A NO314783B1 NO 314783 B1 NO314783 B1 NO 314783B1 NO 19981073 A NO19981073 A NO 19981073A NO 981073 A NO981073 A NO 981073A NO 314783 B1 NO314783 B1 NO 314783B1
- Authority
- NO
- Norway
- Prior art keywords
- darifenacin
- pharmaceutically acceptable
- released
- dosage form
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9518953.6A GB9518953D0 (en) | 1995-09-15 | 1995-09-15 | Pharmaceutical formulations |
PCT/EP1996/003719 WO1997009980A1 (en) | 1995-09-15 | 1996-08-21 | Pharmaceutical formulations containing darifenacin |
Publications (3)
Publication Number | Publication Date |
---|---|
NO981073L NO981073L (no) | 1998-03-11 |
NO981073D0 NO981073D0 (no) | 1998-03-11 |
NO314783B1 true NO314783B1 (no) | 2003-05-26 |
Family
ID=10780813
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19981073A NO314783B1 (no) | 1995-09-15 | 1998-03-11 | Farmasoytiske formuleringer inneholdende darifenacin |
NO2005009C NO2005009I2 (no) | 1995-09-15 | 2005-04-08 | Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2005009C NO2005009I2 (no) | 1995-09-15 | 2005-04-08 | Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid |
Country Status (32)
Country | Link |
---|---|
US (1) | US6106864A (cs) |
EP (2) | EP1245231B1 (cs) |
JP (1) | JP3403203B2 (cs) |
KR (1) | KR100348585B1 (cs) |
CN (1) | CN1303998C (cs) |
AR (1) | AR005231A1 (cs) |
AT (2) | ATE269076T1 (cs) |
BR (2) | BR9610153A (cs) |
CA (1) | CA2230314C (cs) |
CO (1) | CO4750822A1 (cs) |
CY (3) | CY2468B1 (cs) |
CZ (1) | CZ294024B6 (cs) |
DE (4) | DE69632753T2 (cs) |
DK (2) | DK0850059T3 (cs) |
EG (1) | EG23826A (cs) |
ES (2) | ES2224002T3 (cs) |
FR (1) | FR05C0019I2 (cs) |
GB (1) | GB9518953D0 (cs) |
HU (2) | HU227397B1 (cs) |
IL (1) | IL122746A (cs) |
LU (1) | LU91163I2 (cs) |
MY (1) | MY125662A (cs) |
NL (1) | NL300190I2 (cs) |
NO (2) | NO314783B1 (cs) |
NZ (1) | NZ316924A (cs) |
PL (1) | PL185604B1 (cs) |
PT (1) | PT1245231E (cs) |
RU (1) | RU2163803C2 (cs) |
TR (1) | TR199800461T1 (cs) |
TW (1) | TW442300B (cs) |
WO (1) | WO1997009980A1 (cs) |
ZA (1) | ZA967745B (cs) |
Families Citing this family (309)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2266070A1 (en) * | 1996-09-19 | 1998-03-26 | American Home Products Corporation | Method of treating urinary incontinence |
US20100137358A1 (en) * | 1996-11-05 | 2010-06-03 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
US7858119B1 (en) * | 2000-05-09 | 2010-12-28 | Amina Odidi | Extended release pharmaceuticals |
US6653339B2 (en) | 2001-08-15 | 2003-11-25 | Pfizer Inc. | Method of treating irritable bowel syndrome |
DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
US7163696B2 (en) * | 2001-10-11 | 2007-01-16 | Pfizer Inc. | Pharmaceutical formulations |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
GB0129962D0 (en) * | 2001-12-14 | 2002-02-06 | Pfizer Ltd | Method of treatment |
GB0207104D0 (en) * | 2002-03-26 | 2002-05-08 | Pfizer Ltd | Stable hydrate of a muscarinic receptor antagonist |
RU2331438C2 (ru) | 2002-12-13 | 2008-08-20 | Уорнер-Ламберт Компани Ллс | Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей |
CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
US20040235857A1 (en) * | 2003-02-11 | 2004-11-25 | Pfizer Inc | Crystalline therapeutic agent |
PA8597401A1 (es) * | 2003-03-14 | 2005-05-24 | Pfizer | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep |
US20040186046A1 (en) * | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
WO2004096810A1 (en) | 2003-04-29 | 2004-11-11 | Pfizer Limited | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
US7268147B2 (en) * | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
EP2112920B1 (en) | 2003-06-26 | 2018-07-25 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US20050043300A1 (en) * | 2003-08-14 | 2005-02-24 | Pfizer Inc. | Piperazine derivatives |
BRPI0414105B8 (pt) * | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de benzimidazolona com atividade agonista do receptor 5-ht4 |
ATE449633T1 (de) | 2003-09-12 | 2009-12-15 | Pfizer | Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern |
RS20060198A (en) * | 2003-10-03 | 2008-09-29 | Pfizer Limited, | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activ ity for the treatment of hiv and inflammation |
GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
US7572799B2 (en) * | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
GB0402491D0 (en) * | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Medicaments |
US7629358B2 (en) * | 2004-03-17 | 2009-12-08 | Pfizer Inc | Compounds useful for the treatment of diseases |
AU2005223483B2 (en) * | 2004-03-18 | 2009-04-23 | Zoetis Llc | N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides |
AP2315A (en) * | 2004-03-23 | 2011-11-04 | Pfizer | Formamide derivatives useful as adrenoceptor. |
US20050215542A1 (en) * | 2004-03-23 | 2005-09-29 | Pfizer Inc | Compounds for the treatment of diseases |
US7538141B2 (en) * | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
ES2317209T3 (es) * | 2004-04-07 | 2009-04-16 | Pfizer Inc. | Pirazolo(4,3-) pirimidinas. |
EA200801608A1 (ru) * | 2004-06-15 | 2008-10-30 | Пфайзер Инк. | Производные бензимидазолонкарбоновой кислоты |
US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
ATE412652T1 (de) | 2004-08-12 | 2008-11-15 | Pfizer | Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
BRPI0513915A (pt) | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
CN101018780B (zh) * | 2004-08-26 | 2012-01-11 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物 |
MX2007005290A (es) * | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
US20060111416A1 (en) * | 2004-11-24 | 2006-05-25 | Lane Charlotte A L | Octahydropyrrolo[3,4-C]pyrrole derivatives |
BRPI0608436A2 (pt) | 2005-03-17 | 2009-12-29 | Pfizer | derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor |
US20110152326A1 (en) * | 2005-03-28 | 2011-06-23 | Takeshi Hanazawa | Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists |
US20080176865A1 (en) * | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
US7645786B2 (en) * | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
US20080146643A1 (en) * | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
CA2612287C (en) * | 2005-06-15 | 2011-01-25 | Pfizer Limited | Substituted arylpyrazoles for use against parasites |
US20070149464A1 (en) * | 2005-06-15 | 2007-06-28 | Pfizer Inc. | Combination |
EP1912968A1 (en) * | 2005-08-04 | 2008-04-23 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
JP2009504628A (ja) * | 2005-08-10 | 2009-02-05 | ファイザー・リミテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
CN103142586A (zh) | 2005-09-02 | 2013-06-12 | 塞拉维达公司 | 治疗疾病的疗法 |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
US20070141684A1 (en) | 2005-12-21 | 2007-06-21 | Pfizer Inc | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
US20090062326A1 (en) * | 2006-03-17 | 2009-03-05 | Spindel Eliot R | M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors |
JP5457830B2 (ja) | 2006-04-03 | 2014-04-02 | オディディ,イサ | オルガノゾル被膜を含む制御放出送達デバイス |
EP2258700A1 (en) | 2006-05-09 | 2010-12-08 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
WO2008017932A2 (en) * | 2006-08-09 | 2008-02-14 | Pfizer Products Inc. | Heterocycles useful as inhibitors of carbonic anhydrase |
WO2008031221A1 (en) * | 2006-09-12 | 2008-03-20 | Cephalin Pharmaceuticals Inc. | Isovaline for treatment of pain |
MX2009000080A (es) * | 2006-09-21 | 2009-01-23 | Raqualia Pharma Inc | Derivados de bencimidazol como inhibidores selectivos de la bomba de acido. |
US8158650B2 (en) | 2006-10-23 | 2012-04-17 | Pfizer Inc. | Substituted phenylmethyl bicyclocarboxyamide compounds |
RU2322998C1 (ru) * | 2006-11-16 | 2008-04-27 | Общество с ограниченной ответственностью "Березовый мир" | Носитель лекарственных и диагностических средств |
MY146087A (en) | 2007-02-02 | 2012-06-29 | Pfizer Prod Inc | Tricyclic compound, compositions, and methods |
EP2160381A2 (en) * | 2007-05-24 | 2010-03-10 | Pfizer Limited | Spirocyclic quinazoline derivatives and their use as pde7 inhibitors |
CN101084891A (zh) * | 2007-06-29 | 2007-12-12 | 北京本草天源药物研究院 | 一种用于口服的达非那新或其药用盐的药物制剂 |
WO2009006413A1 (en) * | 2007-06-30 | 2009-01-08 | Auspex Pharmaceuticals, Inc. | Substituted pyrrolidines |
US8323695B2 (en) | 2007-08-13 | 2012-12-04 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
CZ300895B6 (cs) * | 2008-01-28 | 2009-09-02 | Zentiva, A. S. | Zpusob prípravy Darifenacinu |
WO2009105887A1 (en) * | 2008-02-26 | 2009-09-03 | Ernest Puil | Cyclic amino acids for the treatment of pain |
WO2009140078A1 (en) * | 2008-05-16 | 2009-11-19 | The Procter & Gamble Company | Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists |
BRPI0912679A2 (pt) * | 2008-05-16 | 2016-01-26 | Axis Inc | composição farmacêutica para o tratamento de fibromialgia |
PL2285357T3 (pl) * | 2008-05-30 | 2014-08-29 | Ucb Pharma Sa | Kompozycja farmaceutyczna zawierająca brivaracetam |
EP2328890B1 (en) * | 2008-08-06 | 2012-01-25 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
EP2163253B1 (en) | 2008-09-15 | 2013-07-17 | ULLRICH, Oliver | Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof |
CN102224142B (zh) | 2008-11-21 | 2015-07-22 | 拉夸里亚创药株式会社 | 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物 |
MA32965B1 (fr) | 2009-01-12 | 2012-01-02 | Pfizer Ltd | Derives de sulfonamides |
CN102369212B (zh) | 2009-03-12 | 2015-12-16 | 哈瑟投资公司 | 具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体 |
EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
EP2236516A1 (en) | 2009-03-31 | 2010-10-06 | Charité-Universitätsmedizin Berlin (Charité) | Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury |
KR20120018813A (ko) | 2009-05-29 | 2012-03-05 | 화이자 리미티드 | 글루코코티코이드 수용체 작용제 |
EP2266563A1 (en) | 2009-06-11 | 2010-12-29 | Charité-Universitätsmedizin Berlin (Charité) | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
US8617763B2 (en) * | 2009-08-12 | 2013-12-31 | Bloom Energy Corporation | Internal reforming anode for solid oxide fuel cells |
JP2013513615A (ja) | 2009-12-11 | 2013-04-22 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 脂肪酸アミドヒドロラーゼのアゾ環状阻害薬 |
WO2011077313A1 (en) | 2009-12-22 | 2011-06-30 | Pfizer Inc. | Piperidinecarboxamides as mpges - 1 inhibitors |
SI2516434T1 (sl) | 2009-12-23 | 2015-10-30 | Takeda Pharmaceutical Company Limited | Zliti heteroaromatski pirolidinoni kot inhibitorji SYK |
GB2479213B (en) | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
JP2013525476A (ja) | 2010-05-04 | 2013-06-20 | ファイザー・インク | Alk阻害剤としての複素環式誘導体 |
WO2011154871A1 (en) | 2010-06-10 | 2011-12-15 | Pfizer Limited | Hepatitis c virus inhibitors |
WO2011161504A1 (en) | 2010-06-23 | 2011-12-29 | Micro Labs Limited | Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof |
CA2803118C (en) | 2010-07-09 | 2015-11-03 | Pfizer Limited | Sulfonamide derivatives as nav 1.7 inhibitors |
WO2012004706A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
JP5830534B2 (ja) | 2010-07-09 | 2015-12-09 | ファイザー・リミテッドPfizer Limited | 化合物 |
EP2593428B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
EP2593432B1 (en) | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
CA2800971A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
JP2013536165A (ja) | 2010-07-12 | 2013-09-19 | ファイザー・リミテッド | 痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体 |
US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
RU2564445C2 (ru) | 2010-11-15 | 2015-10-10 | ВииВ Хелткер ЮКей Лимитед | Ингибиторы репликации вич |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
CN102048706B (zh) * | 2011-01-12 | 2012-02-22 | 山东创新药物研发有限公司 | 一种氢溴酸达非那新缓释片及制备方法 |
WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
CN103384672B (zh) | 2011-02-25 | 2016-09-28 | 武田药品工业株式会社 | N-取代的噁嗪并喋啶和噁嗪并喋啶酮 |
WO2012120398A1 (en) | 2011-03-04 | 2012-09-13 | Pfizer Limited | Aryl substituted carboxamide derivatives as trpm8 modulators |
CA2832291C (en) | 2011-04-05 | 2015-12-01 | Pfizer Limited | Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
WO2012154775A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder |
AU2012253667B2 (en) | 2011-05-10 | 2017-06-01 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
CA2836372C (en) | 2011-05-18 | 2020-09-22 | Raqualia Pharma Inc. | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
AU2012291744A1 (en) | 2011-08-02 | 2014-02-20 | Pfizer Inc. | Crizotinib for use in the treatment of cancer |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
WO2013057624A1 (en) | 2011-10-19 | 2013-04-25 | Ah Usa 42 Llc | Use of aminoacetonitrile derivatives against endoparasites |
JP5363636B2 (ja) | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
JP5946538B2 (ja) | 2011-10-26 | 2016-07-06 | ファイザー・リミテッドPfizer Limited | ナトリウムチャネルモジュレーターとして有用な(4−フェニルイミダゾール−2−イル)エチルアミン誘導体 |
JP6158817B2 (ja) | 2011-10-28 | 2017-07-05 | インヒビタクシン リミテッド | 治療に有用なピリダジン誘導体 |
ES2593533T3 (es) | 2011-12-15 | 2016-12-09 | Pfizer Limited | Derivados de sulfonamida |
WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
CN102600096B (zh) * | 2011-12-29 | 2016-08-10 | 北京科信必成医药科技发展有限公司 | 一种达非那新缓释制剂及其制备方法 |
CN102579379B (zh) * | 2011-12-29 | 2016-08-10 | 北京科信必成医药科技发展有限公司 | 一种药物缓释制剂及其制备方法 |
JP6067031B2 (ja) | 2012-01-04 | 2017-01-25 | ファイザー・リミテッドPfizer Limited | N−アミノスルホニルベンズアミド |
WO2013114250A1 (en) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
EA026155B9 (ru) | 2012-03-06 | 2017-06-30 | Пфайзер Инк. | Макроциклические производные для лечения пролиферативных заболеваний |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
US9353062B2 (en) | 2012-04-04 | 2016-05-31 | Hangzhouderenyucheng Biotechnology Ltd | Substituted quinolines as bruton's tyrosine kinases inhibitors |
TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
WO2014039831A1 (en) | 2012-09-07 | 2014-03-13 | Takeda Pharmaceutical Company Limited | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES |
US9533989B2 (en) | 2012-09-18 | 2017-01-03 | Ziarco Pharma Ltd. | Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors |
WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
WO2014053965A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Tropomyosin-related kinase inhibitors |
EP2903989A1 (en) | 2012-10-04 | 2015-08-12 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors |
CA2885259A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
AP3861A (en) | 2012-11-08 | 2016-10-31 | Pfizer | Heteroaromatic compounds as dopamine d1 ligands |
JP5857168B2 (ja) | 2012-11-08 | 2016-02-10 | ファイザー・インク | ドーパミンd1リガンドとしての複素芳香族化合物およびその使用 |
CN108658964B (zh) | 2012-11-21 | 2021-07-02 | 拉夸里亚创药株式会社 | 多晶型物 |
CA2891234C (en) | 2012-12-03 | 2017-03-07 | Pfizer Inc. | Selective androgen receptor modulators |
UA112028C2 (uk) | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
AR094797A1 (es) | 2013-02-15 | 2015-08-26 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
TR201816077T4 (tr) | 2013-02-21 | 2018-11-21 | Pfizer | Seçici bir cdk4/6 inhibitörünün katı formları. |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
JP2016510787A (ja) * | 2013-03-13 | 2016-04-11 | ラシオファルム ゲーエムベーハー | クリゾチニブを含む剤形 |
EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
WO2014181213A1 (en) | 2013-05-10 | 2014-11-13 | Pfizer Inc. | Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide |
EP2997084A4 (en) | 2013-05-17 | 2016-10-12 | Acupac Packaging Inc | ANHYDROUS HYDROGEL COMPOSITION |
TR201907981T4 (tr) | 2013-06-27 | 2019-06-21 | Pfizer | Heteroaromatik bileşikler ve bunların dopamin d1 ligandları olarak kullanımı. |
CN104513253A (zh) | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
CA2934010A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2015092614A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Inc. | Activating notch alterations in breast cancer |
UY35945A (es) | 2014-01-09 | 2015-08-31 | Takeda Pharmaceutical | Derivados de azaindol |
WO2015106014A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
US20170197939A1 (en) | 2014-04-15 | 2017-07-13 | Pfizer Inc. | Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety |
CR20160493A (es) | 2014-04-25 | 2016-12-16 | Pfizer | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 |
EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
MD20160109A2 (ro) | 2014-04-25 | 2017-04-30 | Pfizer Inc. | Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 |
WO2015166366A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015170218A1 (en) | 2014-05-07 | 2015-11-12 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
AP2016009562A0 (en) | 2014-05-14 | 2016-11-30 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
KR101817889B1 (ko) | 2014-05-15 | 2018-01-11 | 화이자 인코포레이티드 | 6-[(4r)-4-메틸-1,2-다이옥사이도-1,2,6-티아다이아지난-2-일]이소퀴놀린-1-카보니트릴의 결정질 형태 |
ES2747989T3 (es) | 2014-05-20 | 2020-03-12 | Raqualia Pharma Inc | Sal de derivado de benzisoxazol |
WO2015181797A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
EP3148587B1 (en) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Carbonitrile derivatives as selective androgen receptor modulators |
ES2664810T3 (es) | 2014-06-12 | 2018-04-23 | Pfizer Limited | Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA |
WO2015193768A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
UA118380C2 (uk) | 2014-06-17 | 2019-01-10 | Пфайзер Інк. | Заміщені сполуки дигідроізохінолінону |
WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2016009303A1 (en) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors |
WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
WO2016034971A1 (en) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Sulfonamides derivatives as urat1 inhibitors |
US10017529B2 (en) | 2014-09-16 | 2018-07-10 | BioPharma Works LLC | Metformin derivatives |
GB201417163D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
GB201417165D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
WO2016067143A1 (en) | 2014-10-28 | 2016-05-06 | Pfizer Inc. | N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels |
WO2016097918A1 (en) | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
NZ734714A (en) | 2015-01-22 | 2023-07-28 | Phytoplant Res S L | Methods of purifying cannabinoids, compositions and kits thereof |
MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
WO2016148674A1 (en) | 2015-03-13 | 2016-09-22 | Endocyte, Inc. | Conjugates for treating diseases |
US10214509B2 (en) | 2015-04-21 | 2019-02-26 | Almirall, S.A. | Amino-substituted heterocyclic derivatives as sodium channel inhibitors |
WO2016193860A1 (en) | 2015-06-04 | 2016-12-08 | Pfizer Inc. | Solid dosage forms of palbociclib |
DK3328849T5 (da) | 2015-07-31 | 2021-02-15 | Pfizer | 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer |
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
EP3386983A1 (en) | 2015-12-10 | 2018-10-17 | Pfizer Limited | 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain |
UY37046A (es) | 2015-12-24 | 2017-07-31 | Takeda Pharmaceuticals Co | Cocristal, método de produccion del mismo,y medicamento que contiene dicho cocristal |
TWI726968B (zh) | 2016-01-07 | 2021-05-11 | 開曼群島商Cs醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
WO2017119732A1 (en) | 2016-01-08 | 2017-07-13 | Samsung Electronics Co., Ltd. | Electronic device and operating method thereof |
WO2017122116A1 (en) | 2016-01-15 | 2017-07-20 | Pfizer Inc. | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
WO2017127073A1 (en) | 2016-01-20 | 2017-07-27 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
EP3426772A4 (en) | 2016-03-09 | 2019-08-28 | Beijing Percans Oncology Co. Ltd. | TUMOR CELLSUSPENSION CULTURES AND RELATED METHODS |
CN109071496B (zh) | 2016-03-31 | 2021-07-30 | 武田药品有限公司 | 异喹啉基三唑酮复合物 |
CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
US11091483B2 (en) | 2016-08-12 | 2021-08-17 | Madera Therapeutics, LLC | Protein kinase regulators |
LT3497103T (lt) | 2016-08-15 | 2021-07-26 | Pfizer Inc. | Piridopirimidinono cdk2/4/6 inhibitoriai |
US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
CA3047729A1 (en) | 2016-12-20 | 2018-06-28 | Oligomerix, Inc. | Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use |
EP3558950B1 (en) | 2016-12-20 | 2023-05-10 | Oligomerix, Inc. | Novel quinazolinones that inhibit the formation of tau oligomers and their method of use |
JP2020506899A (ja) | 2017-01-20 | 2020-03-05 | ファイザー・インク | Magl阻害薬としての1,1,1−トリフルオロ−3−ヒドロキシプロパン−2−イルカルバマート誘導体 |
AU2018208848A1 (en) | 2017-01-23 | 2019-07-18 | Pfizer Inc., | Heterocyclic spiro compounds as MAGL inhibitors |
BR112019015069A2 (pt) | 2017-01-24 | 2020-03-03 | Pfizer Inc. | Derivados de caliqueamicina e conjugados de anticorpo-fármaco dos mesmos |
US11426397B2 (en) | 2017-03-26 | 2022-08-30 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 |
JOP20180057A1 (ar) | 2017-06-15 | 2019-01-30 | Takeda Pharmaceuticals Co | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |
EP3642198B1 (en) | 2017-06-22 | 2022-03-16 | Curadev Pharma Limited | Small molecule modulators of human sting |
US11773132B2 (en) | 2017-08-30 | 2023-10-03 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cyclic di-nucleotides as stimulator of interferon genes modulators |
CA3074304A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
TW201920108A (zh) | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物 |
CN111356478A (zh) | 2017-11-14 | 2020-06-30 | 辉瑞大药厂 | Ezh2抑制剂组合疗法 |
CA3089490A1 (en) | 2018-01-29 | 2019-08-01 | Phytoplant Research S.L | Methods of purifying cannabinoids using liquid:liquid chromatography |
TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
TW201942116A (zh) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
US20200405809A1 (en) | 2018-02-27 | 2020-12-31 | Pfizer Inc. | Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor |
TWI834637B (zh) | 2018-03-01 | 2024-03-11 | 日商武田藥品工業有限公司 | 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯 |
LT3784664T (lt) | 2018-04-26 | 2025-03-25 | Pfizer Inc. | 2-amino-piridino arba 2-amino piridino dariniai kaip nuo ciklino priklausomos kinazės inhibitoriai |
WO2019243823A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Azaheterocyclic small molecule modulators of human sting |
AU2019304198A1 (en) | 2018-07-19 | 2021-02-04 | Pfizer Inc. | Heterocyclic spiro compounds as MAGL inhibitors |
WO2020076728A1 (en) | 2018-10-08 | 2020-04-16 | Takeda Pharmaceutical Company Limited | SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR |
US11142525B2 (en) | 2018-11-15 | 2021-10-12 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
CN113330015A (zh) | 2019-01-23 | 2021-08-31 | 辉瑞大药厂 | 已知四氢异喹啉衍生物的单磷酸盐水合物盐的多晶型物形式 |
KR102732207B1 (ko) | 2019-01-31 | 2024-11-22 | 화이자 인코포레이티드 | Cdk2에 대한 억제 활성을 갖는 3-카본일아미노-5-사이클로펜틸-1h-피라졸 화합물 |
US20220125777A1 (en) | 2019-02-01 | 2022-04-28 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
CA3131740A1 (en) | 2019-02-27 | 2020-09-03 | Madera Therapeutics, LLC | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents |
AR118471A1 (es) | 2019-03-22 | 2021-10-06 | Takeda Pharmaceuticals Co | Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2 |
GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
CR20210544A (es) | 2019-04-29 | 2022-03-30 | Solent Therapeutics Llc | DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2 |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
TW202116734A (zh) | 2019-07-25 | 2021-05-01 | 印度商裘拉德製藥私人有限公司 | 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑 |
GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
WO2021055326A1 (en) | 2019-09-16 | 2021-03-25 | Takeda Pharmaceutical Company Limited | Azole-fused pyridazin-3(2h)-one derivatives |
KR20220141328A (ko) | 2020-02-12 | 2022-10-19 | 큐라데브 파마 프라이버트 리미티드 | 소분자 sting 길항제 |
WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
AR121682A1 (es) | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 |
AR121683A1 (es) | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 |
JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置 |
CN115461340A (zh) | 2020-04-08 | 2022-12-09 | 特殊治疗有限公司 | 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 |
CA3181415A1 (en) | 2020-05-01 | 2021-11-04 | Pfizer Inc. | Azalactam compounds as hpk1 inhibitors |
IL297456A (en) | 2020-05-04 | 2022-12-01 | Takeda Pharmaceuticals Co | n-(piperidin-4-yl)benzamide derivatives are active in Nahor |
WO2021224818A1 (en) | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
CA3185027A1 (en) | 2020-05-28 | 2021-12-02 | Mission Therapeutics Limited | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mi tochondrial dysfunction |
CN115698001A (zh) | 2020-06-04 | 2023-02-03 | 特殊治疗有限公司 | 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 |
IL298785A (en) | 2020-06-08 | 2023-02-01 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Her2突變抑制劑 |
US20240116937A1 (en) | 2020-07-15 | 2024-04-11 | Pfizer Inc. | Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol |
US20230242539A1 (en) | 2020-07-15 | 2023-08-03 | Pfizer Inc. | Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride |
US20230321042A1 (en) | 2020-07-20 | 2023-10-12 | Pfizer Inc. | Combination therapy |
WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
GB202011812D0 (en) | 2020-07-29 | 2020-09-09 | Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid | Compounds |
GB202011811D0 (en) | 2020-07-29 | 2020-09-09 | Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid | Compounds |
US20240000783A1 (en) | 2020-08-13 | 2024-01-04 | Pfizer Inc. | Combination therapy |
EP4578450A3 (en) | 2020-09-15 | 2025-07-16 | Pfizer Inc. | Solid forms of a cdk4 inhibitor |
TW202229239A (zh) | 2020-09-23 | 2022-08-01 | 日商武田藥品工業股份有限公司 | 作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物 |
CA3195121A1 (en) | 2020-10-09 | 2022-04-14 | Robert A. Volkmann | Heteroaryl amide inhibitors of cd38 |
GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
IL303932A (en) | 2020-12-22 | 2023-08-01 | Pfizer | Solid forms of EIF4E inhibitor |
EP4267563A1 (en) | 2020-12-24 | 2023-11-01 | Pfizer Inc. | Solid forms of a cdk2 inhibitor |
US11964978B2 (en) | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
BR112023018906A2 (pt) | 2021-03-24 | 2023-10-10 | Astellas Pharma Inc | Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr |
MX2023011633A (es) | 2021-03-31 | 2023-12-15 | Sevenless Therapeutics Ltd | Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor. |
GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
KR20240025504A (ko) | 2021-04-07 | 2024-02-27 | 라이프아크 | Ulk1/2 억제제 및 이의 용도 |
WO2022229846A1 (en) | 2021-04-29 | 2022-11-03 | Pfizer Inc. | Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor |
AU2022297733B2 (en) | 2021-06-26 | 2025-04-24 | Array Biopharma Inc. | Her2 mutation inhibitors |
WO2023002362A1 (en) | 2021-07-22 | 2023-01-26 | Pfizer Inc. | Treatment of hematological malignancy |
IL310705A (en) | 2021-08-11 | 2024-04-01 | Curadev Pharma Pvt Ltd | Small molecule STING antagonists |
JP2024529089A (ja) | 2021-08-11 | 2024-08-01 | キュラデブ ファーマ ピーブイティー. リミテッド | Stingアンタゴニストとしての小分子ウレア誘導体 |
WO2023084459A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating sars-cov-2 |
EP4441052A1 (en) | 2021-12-01 | 2024-10-09 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Compounds |
US20250034122A1 (en) | 2021-12-01 | 2025-01-30 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
IL312980A (en) | 2021-12-02 | 2024-07-01 | Pfizer | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer |
JP2025511255A (ja) | 2022-03-30 | 2025-04-15 | 武田薬品工業株式会社 | N-(ピロリジン-3-イルまたはピペリジン-4-イル)アセトアミド誘導体 |
AR129012A1 (es) | 2022-04-07 | 2024-07-03 | Takeda Pharmaceuticals Co | Derivados de piridazina fusionados |
WO2024013567A1 (en) | 2022-07-15 | 2024-01-18 | Jazz Pharmaceuticals Ireland Limited | Biaryl ether urea compounds as faah inhibitors |
AU2023316863A1 (en) | 2022-07-29 | 2025-02-13 | Pfizer Inc. | Novel acc inhibitors |
JP2025526692A (ja) | 2022-08-10 | 2025-08-15 | 武田薬品工業株式会社 | 複素環式化合物 |
WO2024033513A1 (en) | 2022-08-11 | 2024-02-15 | Diaccurate | Compounds for treating cancer |
EP4598538A1 (en) | 2022-10-05 | 2025-08-13 | Sevenless Therapeutics Limited | New treatments for pain |
TW202434599A (zh) | 2022-11-15 | 2024-09-01 | 英商克拉德夫製藥有限公司 | 造血前驅細胞激酶1之吡啶酮及嘧啶酮抑制劑 |
US20240238250A1 (en) | 2023-01-13 | 2024-07-18 | Neurim Pharmaceuticals (1991) Ltd. | Method of using piromelatine for treating parasomnias associated with loss of rem sleep atonia |
AU2024211867A1 (en) | 2023-01-26 | 2025-07-17 | Takeda Pharmaceutical Company Limited | 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases |
WO2024214046A1 (en) | 2023-04-14 | 2024-10-17 | Takeda Pharmaceutical Company Limited | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 |
WO2024251978A1 (en) | 2023-06-09 | 2024-12-12 | Institut Gustave Roussy | Drug conjugate targeting ctla4, products comprising the same and therapeutic uses thereof |
WO2024258856A1 (en) | 2023-06-12 | 2024-12-19 | Arvinas Operations, Inc. | Solid oral dosage forms of estrogen receptor degraders |
GB2631397A (en) | 2023-06-28 | 2025-01-08 | Sevenless Therapeutics Ltd | New treatments for pain |
US20250057848A1 (en) | 2023-08-14 | 2025-02-20 | Neurim Pharmaceuticals (1991) Ltd. | Gal475 compositions and methods of use thereof |
GB2633813A (en) | 2023-09-21 | 2025-03-26 | Sevenless Therapeutics Ltd | New treatments for pain |
WO2025074305A1 (en) | 2023-10-04 | 2025-04-10 | Takeda Pharmaceutical Company Limited | N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives |
WO2025083426A1 (en) | 2023-10-20 | 2025-04-24 | Sevenless Therapeutics Limited | New treatments for pain |
GB202319181D0 (en) | 2023-12-14 | 2024-01-31 | Imperial College Innovations Ltd | Nora Inhibitors |
WO2025146548A1 (en) | 2024-01-04 | 2025-07-10 | Sevenless Therapeutics Limited | Sos1 inhibitors useful to treat pain and cancer |
WO2025168601A1 (en) | 2024-02-05 | 2025-08-14 | Evexta Bio | Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8906166D0 (en) * | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
US5233053A (en) * | 1989-03-17 | 1993-08-03 | Pfizer Inc. | Pyrrolidine derivatives |
PT93637A (pt) * | 1989-04-20 | 1990-11-20 | Procter & Gamble | Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal |
GB9400600D0 (en) * | 1994-01-14 | 1994-03-09 | Pfizer Ltd | Treatment of motion seckness |
-
1995
- 1995-09-15 GB GBGB9518953.6A patent/GB9518953D0/en active Pending
-
1996
- 1996-08-06 TW TW085109518A patent/TW442300B/zh not_active IP Right Cessation
- 1996-08-21 RU RU98107322/14A patent/RU2163803C2/ru active Protection Beyond IP Right Term
- 1996-08-21 KR KR1019980701907A patent/KR100348585B1/ko not_active Expired - Lifetime
- 1996-08-21 US US09/029,072 patent/US6106864A/en not_active Expired - Lifetime
- 1996-08-21 DE DE69632753T patent/DE69632753T2/de not_active Expired - Lifetime
- 1996-08-21 CA CA002230314A patent/CA2230314C/en not_active Expired - Lifetime
- 1996-08-21 DK DK96930085T patent/DK0850059T3/da active
- 1996-08-21 ES ES02015165T patent/ES2224002T3/es not_active Expired - Lifetime
- 1996-08-21 WO PCT/EP1996/003719 patent/WO1997009980A1/en active IP Right Grant
- 1996-08-21 HU HU0500976A patent/HU227397B1/hu unknown
- 1996-08-21 CZ CZ1998732A patent/CZ294024B6/cs not_active IP Right Cessation
- 1996-08-21 NZ NZ316924A patent/NZ316924A/xx not_active IP Right Cessation
- 1996-08-21 PL PL96325598A patent/PL185604B1/pl unknown
- 1996-08-21 JP JP51160297A patent/JP3403203B2/ja not_active Expired - Lifetime
- 1996-08-21 PT PT02015165T patent/PT1245231E/pt unknown
- 1996-08-21 AT AT02015165T patent/ATE269076T1/de active
- 1996-08-21 TR TR1998/00461T patent/TR199800461T1/xx unknown
- 1996-08-21 HU HU9802339A patent/HU225236B1/hu active Protection Beyond IP Right Term
- 1996-08-21 DE DE69626397T patent/DE69626397T2/de not_active Expired - Lifetime
- 1996-08-21 CN CNB961969776A patent/CN1303998C/zh not_active Expired - Lifetime
- 1996-08-21 BR BR9610153A patent/BR9610153A/pt not_active Application Discontinuation
- 1996-08-21 DE DE200512000024 patent/DE122005000024I1/de active Pending
- 1996-08-21 DE DE1996626397 patent/DE122005000024I2/de active Active
- 1996-08-21 ES ES96930085T patent/ES2188782T3/es not_active Expired - Lifetime
- 1996-08-21 EP EP02015165A patent/EP1245231B1/en not_active Expired - Lifetime
- 1996-08-21 DK DK02015165T patent/DK1245231T3/da active
- 1996-08-21 IL IL12274696A patent/IL122746A/xx not_active IP Right Cessation
- 1996-08-21 EP EP96930085A patent/EP0850059B1/en not_active Expired - Lifetime
- 1996-08-21 AT AT96930085T patent/ATE233090T1/de active
- 1996-08-21 BR BR122012014331A patent/BR122012014331B8/pt not_active IP Right Cessation
- 1996-09-11 AR ARP960104304A patent/AR005231A1/es active IP Right Grant
- 1996-09-12 EG EG82296A patent/EG23826A/xx active
- 1996-09-13 CO CO96049000A patent/CO4750822A1/es unknown
- 1996-09-13 MY MYPI96003784A patent/MY125662A/en unknown
- 1996-09-13 ZA ZA9607745A patent/ZA967745B/xx unknown
-
1998
- 1998-03-11 NO NO19981073A patent/NO314783B1/no not_active IP Right Cessation
-
2004
- 2004-08-10 CY CY0400059A patent/CY2468B1/xx unknown
-
2005
- 2005-03-25 NL NL300190C patent/NL300190I2/nl unknown
- 2005-04-08 NO NO2005009C patent/NO2005009I2/no unknown
- 2005-04-14 CY CY200500007C patent/CY2005007I2/el unknown
- 2005-04-19 FR FR05C0019C patent/FR05C0019I2/fr active Active
- 2005-04-19 LU LU91163C patent/LU91163I2/fr unknown
- 2005-11-10 CY CY0500059A patent/CY2585B2/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO314783B1 (no) | Farmasoytiske formuleringer inneholdende darifenacin | |
AU2004268663B2 (en) | Sustained release dosage forms of ziprasidone | |
KR20040037026A (ko) | 심장병 및 순환성 질병을 치료하고 예방하기 위한 하루1회 요법용 제어방출형 경구 약제학적 조성물 | |
WO2011039686A1 (en) | Latrepirdine oral sustained release dosage forms | |
US20160243002A1 (en) | Multilayer minitablets with different release rates | |
US20040146556A1 (en) | Oral extended release tablets and methods of making and using the same | |
WO2003017983A1 (en) | A new extended release oral dosage form | |
AU703866C (en) | Pharmaceutical formulations containing darifenacin | |
AU726814B2 (en) | Pharmaceutical formulations containing darifenacin | |
MXPA98002026A (en) | Pharmaceutical formulations containing darifenac | |
WO2003017984A1 (en) | A new extended release oral dosage form | |
AU2002327992A1 (en) | a new extended release oral dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: EMSELEX (7,5 MG DEPOTTABLETT MED 7,14,28,49,56 OG 98 TABLETTER I BLISTERPAKNING OG 15 MG DEPOTTABLETT MED 7,14,28,49,56 OG 98 TABLETTER I BLISTERPAKNING); NAT. REG.NO/DATE: NO , 04/294/1-12 20041022 Spc suppl protection certif: 2005009 Filing date: 20050408 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: EMSELEX (7,5 MG DEPOTTABLETT MED 7,14,28,49,56 OG 98 TABLETTER I BLISTERPAKNING OG 15 MG DEPOTTABLETT MED 7,14,28,49,56 OG 98 TABLETTER I BLISTERPAKNING); NAT. REG.NO/DATE: NO , 04/294/1-12 20041022 Spc suppl protection certif: 2005009 Filing date: 20050408 Extension date: 20191022 Effective date: 20061120 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERUS LABS NETHERLANDS BV, NL |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Free format text: PRODUCT NAME: EMSELEX-DARIFENACIN. IUPAC-NAVN: (S)-2-{1-¢2-(2,3-DIHYDROBENZOFURAN-5-YL)ETYL!-3-PYRROLIDINYL}-2,2-DIFENYLACETAMID Spc suppl protection certif: 2005009 |